{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:34:58Z","timestamp":1764603298014,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T00:00:00Z","timestamp":1413763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Hydrochlorothiazide is a diuretic used to treat hypertension that belongs to class IV of the Biopharmaceutics Classification System. The drug was evaluated by quality control, thermal characterization tests, and pharmaceutical formulation compatibility studies. It was concluded that the generic drug, Lab 2, was not a pharmaceutical equivalent. The compounded drugs, Lab 5 and Lab 6, produced unsatisfactory but expected results, since there is no requirement for dissolution and dissolution profile testing for the commercialization of these products. In a compatibility study, lactose and mannitol were shown to be incompatible with HCTZ, which may explain the lack of equivalence of the generic pharmaceutical product, associated with other situations.<\/jats:p>","DOI":"10.3390\/molecules191016824","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T10:14:47Z","timestamp":1413800087000},"page":"16824-16836","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Quality Evaluation of Pharmaceutical Formulations  Containing Hydrochlorothiazide"],"prefix":"10.3390","volume":"19","author":[{"given":"Marcelo","family":"De Oliveira","sequence":"first","affiliation":[{"name":"Departamento de Ci\u00eancias da Sa\u00fade, Centro Universit\u00e1rio Norte do Esp\u00edrito Santo, UFES,  Rodovia BR 101 Norte, km 60, 29932-540 S\u00e3o Mateus, ES, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica, Universidade Federal de Minas Gerais, Av. Pres. Ant\u00f4nio Carlos,  6627-31270-901 Belo Horizonte, MG, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"Silva","sequence":"additional","affiliation":[{"name":"Departamento de Ci\u00eancias da Sa\u00fade, Centro Universit\u00e1rio Norte do Esp\u00edrito Santo, UFES,  Rodovia BR 101 Norte, km 60, 29932-540 S\u00e3o Mateus, ES, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2014,10,20]]},"reference":[{"key":"ref_1","unstructured":"Gilman, A.G. (2006). Goodman & Gilman\u2019s\u2014The Pharmacological Basis of Therapeutics, McGraw-Hill Interamericana. [11th ed.]."},{"key":"ref_2","unstructured":"National Agency of Sanitary Vigilance (2010). Brazilian Pharmacopoeia, National Agency of Sanitary Vigilance. [5th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular properties of WHO essential drugs and provisional biopharmaceutical classification","volume":"1","author":"Amidon","year":"2004","journal-title":"Mol. Pharm."},{"key":"ref_4","unstructured":"Aulton, M.E. (2006). Delineation of Dosage Forms, ARTMED. [2nd ed.]."},{"key":"ref_5","first-page":"265","article-title":"Evaluation of the dissolution profile of hydrochlorothiazide tablets marketed in Brazil","volume":"28","author":"Mahle","year":"2007","journal-title":"J. Basic Appl. Pharm. Sci."},{"key":"ref_6","unstructured":"Brazil. National Agency of Sanitary Vigilance Drugs Reference, Available online:http:\/\/www.anvisa.gov.br\/medicamentos\/referencia\/lmr_a.pdf."},{"key":"ref_7","unstructured":"National Agency of Sanitary Vigilance (Resolution\u2014RDC No. 67, 2007). Resolution\u2014RDC No. 67, Section 1, Good Practices for Handling of Magistral Preparations and Workshop for Human Use in Pharmacies."},{"key":"ref_8","unstructured":"National Agency of Sanitary Vigilance (Resolution\u2014RDC n\u00ba 31, 2010). Resolution\u2014RDC n\u00ba 31, Section 1, Carrying out of Pharmaceutical Equivalence and Comparative Dissolution Profile."},{"key":"ref_9","unstructured":"National Agency of Sanitary Vigilance (Resolution\u2014RDC n\u00ba 17, 2007). Resolution\u2014RDC n\u00ba 17, Technical Regulation of Similar Drugs, 2007."},{"key":"ref_10","unstructured":"National Agency of Sanitary Vigilance (Resolution\u2014RDC n\u00ba 16, 2007). Resolution\u2014RDC n\u00ba 16, Technical Regulation of Generic Drugs, 2007."},{"key":"ref_11","unstructured":"Gasparotto, F.S. Factors Related to the Synthesis of Raw Materials that may Alter the Bioavailability of Generic Drugs. Available online:http:\/\/www.lume.ufrgs.br\/bitstream\/handle\/10183\/5395\/000469676.pdf?sequence=1."},{"key":"ref_12","unstructured":"ICH Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Available online:http:\/\/www.ich.org\/products\/guidelines\/quality\/quality-single\/article\/specifications-test-procedures-and-acceptance-criteria-for-new-drug-substances-and-new-drug-produc.html."},{"key":"ref_13","unstructured":"Guidance for Industry: ANDAs: Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information, Available online:http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072866.pdf."},{"key":"ref_14","unstructured":"National Agency of Sanitary Vigilance (Resolution RE No. 1, 2005). Resolution RE No. 1, Publication of the Guide to Realization of Stability Studies, 2005."},{"key":"ref_15","unstructured":"ICH Stability Testing of New Drug Substances and Products. Available online:http:\/\/www.ich.org\/products\/guidelines\/quality\/quality-single\/article\/stability-testing-of-new-drug-substances-and-products.html."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1590\/S0100-40422011000700022","article-title":"Thermal analysis applied to drugs and pharmaceutical formulations in pharmaceutical industry","volume":"37","author":"Oliveira","year":"2011","journal-title":"Qu\u00edm. Nova"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1590\/S0100-40422010000800007","article-title":"An\u00e1lise t\u00e9rmica aplicada \u00e0 caracteriza\u00e7\u00e3o de sinvastatina em formula\u00e7\u00f5es farmac\u00eauticas","volume":"33","author":"Oliveira","year":"2010","journal-title":"Qu\u00edm. Nova"},{"key":"ref_18","first-page":"73","article-title":"Thermal characterization of atorvastatin and compatibility studies of pharmaceutical formulations","volume":"1","author":"Yoshida","year":"2012","journal-title":"Braz. J. Thermal Anal."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10973-011-1510-0","article-title":"Thermal characterization of lovastatin in pharmaceutical formulations","volume":"106","author":"Yoshida","year":"2011","journal-title":"J. Thermal Anal. Calor."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.3390\/molecules15042439","article-title":"Thermal analysis applied to verapamil hydrochloride characterization in pharmaceutical formulations","volume":"15","author":"Yoshida","year":"2010","journal-title":"Molecules"},{"key":"ref_21","first-page":"3","article-title":"Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: A comprehensive review","volume":"1","author":"Bharate","year":"2010","journal-title":"J. Excip. Food Chem."},{"key":"ref_22","unstructured":"Thermalcal 15 dez. Available online:http:\/\/thermalcal.com."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0731-7085(98)00011-9","article-title":"An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles","volume":"17","author":"Anderson","year":"1998","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S1984-82502012000400024","article-title":"Developing methods to compare tablet formulations of atorvastatin","volume":"48","author":"Oliveira","year":"2012","journal-title":"Braz. J. Pharm. Sci."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/19\/10\/16824\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:17:09Z","timestamp":1760217429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/19\/10\/16824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,20]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10]]}},"alternative-id":["molecules191016824"],"URL":"https:\/\/doi.org\/10.3390\/molecules191016824","relation":{},"ISSN":["1420-3049"],"issn-type":[{"type":"electronic","value":"1420-3049"}],"subject":[],"published":{"date-parts":[[2014,10,20]]}}}